Vaccines and profit – a test case for stewardship
by Mark Goyder with No Comments
November 16, 2020
So… on the day their partners BioNTec announced the success of their vaccine trial, Albert Bourla, the CEO of Pfizer …
Why ESG isn’t enough
by with No Comments
November 10, 2020
The ESG label is now used so frequently that it is in danger of becoming a substitute for thought.
What …